Pierpaolo Caretto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pierpaolo Caretto has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Baggiano
Department of Perioperative Cardiology and Cardiovascular Imaging, Centro Cardiologico Monzino, IRCCS, 20138 Milan, Italy
1 shared publication - Andrea Igoren Guaricci
Cardiovascular Disease Section, Interdisciplinary Department of Medicine (DIM), University of Bari “Aldo Moro”, University Hospital Consortium, Polyclinic of Bari, 70124 Bari, Italy
1 shared publication - Cinzia Forleo
Cardiovascular Disease Section, Interdisciplinary Department of Medicine (DIM), University of Bari “Aldo Moro”, University Hospital Consortium, Polyclinic of Bari, 70124 Bari, Italy
1 shared publication - Eugenio Carulli
Cardiology Unit, Interdisciplinary Department of Medicine (DIM), University of Bari “Aldo Moro”, University Hospital Consortium Polyclinic of Bari, Piazza G. Cesare 11, 70124 Bari, Italy
1 shared publication - Gianluca Pontone
Department of perioperative Cardiology and Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy; Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
1 shared publication - Ilaria Dentamaro
University Cardiology Unit, Interdisciplinary Department of Medicine, Polyclinic University Hospital, University of Bari “Aldo Moro”, 70124 Bari, Italy
1 shared publication
Latest Publications
- Open Access
- 27 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7195
Overcoming Resistance in Anderson–Fabry Disease: Current Therapeutic Challenges and Future Perspectives
Anderson–Fabry disease (AFD) remains a therapeutic challenge despite advances in early diagnosis and the availability of enzyme replacement therapies (ERTs). While early initiation of therapy can mitigate disease progression, resistance mechanisms—such as the development of anti-drug antibodies—limit the efficacy of current treatments, particularly in patients with severe genetic variants. Chaperone therapy provides a targeted option for a subset of patients, yet significant gaps remain in treating those with complete enzyme deficiency. This perspective article explores the existing therapeutic landscape and reflects on emerging treatments, such as mRNA and gene therapies, which hold promise for overcoming the resistance mechanisms. By addressing the limitations of current pharmacological options and considering future innovations, this article aims to outline the path forward for more effective and personalized treatment strategies in Anderson–Fabry disease.
- 27 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7195
Open AccessOvercoming Resistance in Anderson–Fabry Disease: Current Therapeutic Challenges and Future Perspectives
Anderson–Fabry disease (AFD) remains a therapeutic challenge despite advances in early diagnosis and the availability of enzyme replacement therapies (ERTs). While early initiation of therapy can mitigate disease progression, resistance mechanisms—such as the development of anti-drug antibodies—limit the efficacy of current treatments, particularly in patients with severe genetic variants. Chaperone therapy provides a targeted option for a subset of patients, yet significant gaps remain in treating those with complete enzyme deficiency. This perspective article explores the existing therapeutic landscape and reflects on emerging treatments, such as mRNA and gene therapies, which hold promise for overcoming the resistance mechanisms. By addressing the limitations of current pharmacological options and considering future innovations, this article aims to outline the path forward for more effective and personalized treatment strategies in Anderson–Fabry disease.